Upcoming symposia

For questions regarding this program please contact Jennifer Bianchini at: jbianchini@ue4u.com or 888-297-1653 ext. 112.

Event Details

Educational Activity

This course is designed to provide a concise summary of recent data pertinent to the treatment of moderate-to-severe psoriasis. The faculty offer expert analysis and insightful perspectives on the potential impact of the latest clinical data.

Target Audience

This symposia series has been developed to meet the educational needs of clinical dermatologists and dermatology professionals who wish to expand their knowledge of psoriatic diseases.

Learning Objectives

Following completion of this activity, participants should be able to:

Review emerging clinical trial data on the biologic treatments of moderate-to-severe psoriasis
Summarize the potential implications of the most recent findings on the biologic treatment of psoriasis
Discuss the new clinical trial data on monoclonal antibodies targeted toward the IL-12/ IL-23 blockade in psoriasis

CME accreditation and designation

The University of Nevada School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians. The University of Nevada School of Medicine designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)^TM.

The University of Nevada's Latest Biologic Advances in Psoriasis is recognized by the American Academy of Dermatology for 1.5 AAD Category 1 CME Credit(s) and may be used toward the American Academy of Dermatology's Continuing Medical Education Award.